Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$3.85MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Joseph Hariri
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 115
- Beta
- 0.54
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -16.90
Financials
Revenue
$3.85M-25.3%Net Income
$675.0KEBITDA
$1.60MFree Cash Flow
$1.45MEPS (diluted)
$0.02-89.1%Shares Outstanding (diluted)
30.30M+743.1%Operating Expenses
$12.16MCash & Debt
$368.0KReturn of Capital
$0.00Revenue by Segment (annual)
$26.55MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $26.55M | $-91.80M | $-3.59 |
| 2024 | $54.22M | $-57.89M | $-2.64 |
| 2023 | $22.77M | $-196.29M | $-11.02 |
| 2022 | $17.98M | $14.19M | $1.01 |
| 2021 | $21.34M | $-100.12M | $-7.87 |
| 2020 | $14.28M | $-208.23M | $-113.06 |
| 2019 | $21.15M | $-211.88M | $-88.75 |
| 2018 | $17.55M | $-1.1K | $0.00 |
Valuation
CELUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·9d ago·Neutral
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
Celularity Announces Naveen Jain to Join Board of Directors FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”), will join its Board of Directors.
View source ↗ - Newsglobenewswire.com·15d ago·Negative
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements Celularity closes $10 million financing in an up to $28 million recapitalization, advancing growth and targeting positive operating cash flow by Q1 2027.
View source ↗ - Newsglobenewswire.com·45d ago·Negative
Celularity Provides Update Regarding Nasdaq Listing Compliance FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q fo…
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Typical surprise +42.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Apr 30$-0.95 vs $-1.50beat
- Fri, Nov 14$-0.88 vs $-1.50beat
- Thu, May 8$-0.84 vs $-1.50beat
- Fri, Dec 6$-0.73 vs $-1.40beat
Estimates and results for CELU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CELU officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CELU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.